Data to Further Inform Design of Phase 2 Studies

BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) December, 2014 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting plasma gelsolin’s (pGSN) role in immune function announced that it has established collaborations with Vanderbilt and Northwestern Universities to analyze plasma gelsolin levels in a well-adjudicated population of community-acquired pneumonia patients. These data will further inform the design of the company’s phase 2 trials.


Recombinant human plasma gelsolin has demonstrated efficacy against both gram positive and gram negative bacteria. This adds to our broad geographic coverage, including a patent granted last year in China. BioAegis is pursuing worldwide patent filings for infectious disease.


Initial Funding Effort to Advance Recombinant Plasma Gelsolin Therapy into Human Trials

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December 3, 2014) BioAegis Therapeutics announces that it has closed its final tranche of an $8MM convertible note round. These funds will be used to advance its clinical program into human clinical trials in severe community-acquired pneumonia.


Patent Covers Therapeutic Uses of Plasma Gelsolin in Renal Failure

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December 3, 2014) BioAegis Therapeutics announces that its portfolio of patents has been expanded with the granting of a second European Patent for plasma gelsolin. Claims in this patent are directed to the treatment of renal failure.


Initial Effort to Elucidate the Role of Plasma Gelsolin in Human Diseases with Significant Inflammatory and Infectious Disease Complications

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2014) BioAegis Therapeutics has announced that it has entered into a research collaboration with the National Institute of Allergy and Infectious Diseases. NIAID, which is one of the 27 research centers that make up the National Institute of Health, conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. This research collaboration will investigate an undisclosed orphan indication, as well as further elucidate the function of plasma gelsolin in immune cells.